China Approves Human Testing for BioNTech’s COVID-19 Vaccine - Android

Shanghai Fosun Pharmaceutical Group said on Friday that its unit has received clinical trial approval from China’s National Medical Products… Read More

The post China Approves Human Testing for BioNTech’s COVID-19 Vaccine appeared first on .

Shanghai Fosun Pharmaceutical Group said on Friday that its unit has received clinical trial approval from China’s National Medical Products Administration for a COVID-19 vaccine candidate developed by German firm BioNTech.

Many potential vaccines for COVID-19 are being studied, and several large clinical trials may report results later this year. If a vaccine is proven safe and effective, it must be approved by national regulators.

WHO is working with partners around the world to help coordinate key steps in this process. Once a safe and effective vaccine is available, WHO will work to facilitate equitable access for the billions of people who will need it. Currently, a few leading economies like Russia, the United States, and China are making headlines for vaccine developments.

The experimental COVID-19 vaccine, BNT162b2, is more than 90% effective based on initial results from large trials outside China, BioNTech’s partner Pfizer Inc said on Monday.

Shanghai Fosun said in a company filing that its unit will begin a Phase II clinical trial in China for the candidate when conditions are optimal.

The post China Approves Human Testing for BioNTech’s COVID-19 Vaccine appeared first on .